p53 and nasopharyngeal carcinoma: a Malaysian study

References

• Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. 2nd version. IARC Press, Lyon 2004
   Google Scholar
• Lim G CC, Halimah Y. Second Report of the National Cancer Registry. Cancer Incidence in Malaysia 2003. National Cancer Registry, Kuala Lumpur 2004, Chapter 2, Selected cancer sites 2003
   Google Scholar
• Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103: 1888–1893
   PubMed Web of Science ®Google Scholar
• Van Tornout J M, Spruck C H, 3rd, Shibata A, et al. Presence of p53 mutations in primary nasopharyngeal carcinoma (NPC) in non-Asians of Los Angeles, California, a low-risk population for NPC. Cancer Epidemiol Biomark Prev 1997; 6: 493–497
   PubMed Web of Science ®Google Scholar
• Lo K W, Mok C H, Huang D P, et al. p53 mutation in human nasopharyngeal carcinomas. Anticancer Res 1992; 12: 1957–1963
   PubMed Web of Science ®Google Scholar
• Chakrani F, Armand J P, Lenoir G, et al. Mutations clustered in exon 5 of the p53 gene in primary nasopharyngeal carcinomas from southeastern Asia. Int J Cancer 1995; 61: 316–320
   PubMed Web of Science ®Google Scholar
• Taweevisit M. Overexpression of p53 and neoplastic cell proliferation in undifferentiated nasopharyngeal carcinoma. Southeast Asian J Trop Med Public Health 2007; 38: 136–140
   PubMedGoogle Scholar
• Porter M J, Field J K, Lee J C, et al. Detection of the tumour suppressor gene p53 in nasopharyngeal carcinoma in Hong Kong Chinese. Anticancer Res 1994; 14: 1357–1360
   PubMed Web of Science ®Google Scholar
• Cadwell C, Zambetti G P. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 2001; 277: 15–30
   PubMed Web of Science ®Google Scholar
• Kim L H, Peh S C. Epstein–Barr virus-associated lymphomas in Malaysia: high frequency of a 30-bp deletion in the viral Latent Membrane Protein-1 (LMP-1) oncogene. J Clin Exp Hematopthol 2003; 43: 11–19
   Google Scholar
• Chang K P, Hao S P, Lin S Y, et al. A lack of association between p53 mutations and recurrent nasopharyngeal carcinomas refractory to radiotherapy. Laryngoscope 2002; 112: 2015–2019
   PubMed Web of Science ®Google Scholar
• Liu Y, Bodmer W F. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci USA 2006; 103: 976–981
   PubMed Web of Science ®Google Scholar
• Concin N, Zeillinger C, Tong D, et al. Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines. Breast Cancer Res Treat 2003; 79: 37–46
   PubMed Web of Science ®Google Scholar
• Edwards R H, Raab-Traub N. Alterations of the p53 gene in Epstein–Barr virus-associated immunodeficiency-related lymphomas. J Virol 1994; 68: 1309–1315
   PubMed Web of Science ®Google Scholar
• Hoe S L, Sam C K. Mutational analysis of p53 and RB2/p130 genes in Malaysian nasopharyngeal carcinoma samples: a preliminary report. Malays J Pathol 2006; 28: 35–39
   PubMedGoogle Scholar
• Corpet F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 1988; 16: 10881–10890
   PubMed Web of Science ®Google Scholar
• Petitjean A, Achatz M I, Borresen-Dale A L, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157–2165
   PubMed Web of Science ®Google Scholar
• Sun Y, Hegamyer G, Cheng Y J, et al. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci USA 1992; 89: 6516–6520
   PubMed Web of Science ®Google Scholar
• Nasrin N, Taiba K, Hannan N, et al. A molecular study of EBV DNA and p53 mutations in nasopharyngeal carcinoma of Saudi Arab patients. Cancer Lett 1994; 82: 189–198
   PubMed Web of Science ®Google Scholar
• Khabir A, Sellami A, Sakka M, et al. Contrasted frequencies of p53 accumulation in the two age groups of North African nasopharyngeal carcinomas. Clin Cancer Res 2000; 6: 3932–3936
   PubMed Web of Science ®Google Scholar
• Agaoglu F Y, Dizdar Y, Dogan O, et al. P53 overexpression in nasopharyngeal carcinoma. In Vivo 2004; 18: 555–560
   PubMed Web of Science ®Google Scholar
• Kropveld A, Rozemuller E H, Leppers F G, et al. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. Lab Invest 1999; 79: 347–353
   PubMed Web of Science ®Google Scholar
• Hartmann A, Blaszyk H, McGovern R M, et al. p53 gene mutations inside and outside of exons 5–8: the patterns differ in breast and other cancers. Oncogene 1995; 10: 681–688
   PubMed Web of Science ®Google Scholar
• Casey G, Lopez M E, Ramos J C, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996; 13: 1971–1981
   PubMed Web of Science ®Google Scholar
• Barber L M, McGrath H E, Meyer S, et al. Constitutional sequence variation in the Fanconi anaemia group C (FANCC) gene in childhood acute myeloid leukaemia. Br J Haematol 2003; 121: 57–62
   PubMed Web of Science ®Google Scholar
• Gross E, Arnold N, Goette J, et al. A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet 1999; 105: 72–78
   PubMed Web of Science ®Google Scholar
• Okamoto A, Hussain S P, Hagiwara K, et al. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 1995; 55: 1448–1451
   PubMed Web of Science ®Google Scholar
• MacGeoch C, Barnes D M, Newton J A, et al. p53 protein detected by immunohistochemical staining is not always mutant. Dis Markers 1993; 11: 239–250
   PubMed Web of Science ®Google Scholar
• Raab-Traub N. Epstein–Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002; 12: 431–441
   PubMed Web of Science ®Google Scholar
• Rickinson A, Kieff E. Fields Virology5th ed. Lippincott Williams & Wilkins, Philadelphia 2007, Chapter 68A, Epstein–Barr virus and its replication
   Google Scholar
• Vera-Sempere F J, Burgos J S, Botella M S, et al. Immunohistochemical expression of Epstein–Barr virus-encoded latent membrane protein (LMP-1) in paraffin sections of EBV-associated nasopharyngeal carcinoma in Spanish patients. Eur J Cancer B Oral Oncol 1996; 32B: 163–168
   PubMed Web of Science ®Google Scholar
• Lin S Y, Tsang N M, Kao S C, et al. Presence of Epstein–Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma. Head Neck 2001; 23: 194–200
   PubMed Web of Science ®Google Scholar
• Li L, Zhou S, Chen X, et al. The activation of p53 mediated by Epstein–Barr virus latent membrane protein 1 in SV40 large T-antigen transformed cells. FEBS Lett 2008; 582: 755–762
   PubMed Web of Science ®Google Scholar
• Zhang Q, Gutsch D, Kenney S. Functional and physical interaction between p53 and BZLF1: implications for Epstein–Barr virus latency. Mol Cell Biol 1994; 14: 1929–1938
   PubMed Web of Science ®Google Scholar
• Pipas J M, Levine A J. Role of T antigen interactions with p53 in tumorigenesis. Semin Cancer Biol 2001; 11: 23–30
   PubMed Web of Science ®Google Scholar
• Sun Y, Yi H, Zhang P F, et al. Identification of differential proteins in nasopharyngeal carcinoma cells with p53 silence by proteome analysis. FEBS Lett 2007; 581: 131–139
   PubMed Web of Science ®Google Scholar
• Kouvidou C, Kanavaros P, Papaioannou D, et al. Expression of bcl-2 and p53 proteins in nasopharyngeal carcinoma. Absence of correlation with the presence of EBV encoded EBER1–2 transcripts and latent membrane protein-1. Clin Mol Pathol 1995; 48: M17–M22
   PubMedGoogle Scholar
• Shi W, Pataki I, MacMillan C, et al. Molecular pathology parameters in human nasopharyngeal carcinoma. Cancer 2002; 94: 1997–2006
   PubMed Web of Science ®Google Scholar